## Sun Young Yim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1123266/publications.pdf

Version: 2024-02-01

516710 161849 3,290 63 16 54 citations g-index h-index papers 64 64 64 7315 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Determinants of reâ€compensation in patients with hepatitis B virusâ€related decompensated cirrhosis starting antiviral therapy. Alimentary Pharmacology and Therapeutics, 2022, 55, 83-96.	3.7	13
2	Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. Cancers, 2022, 14, 385.	3.7	6
3	Two distinct stem cellâ€like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials. Cancer Communications, 2022, 42, 179-183.	9.2	3
4	Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. Hepatology, 2022, 76, 1634-1648.	7.3	10
5	Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study. Diagnostics, 2022, 12, 663.	2.6	7
6	Pathological predictive factors for late recurrence of hepatocellular carcinoma in chronic liver disease. Liver International, 2021, 41, 1662-1674.	3.9	3
7	Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Gut and Liver, 2021, 15, 284-294.	2.9	33
8	Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients. Journal of Clinical Medicine, 2021, 10, 1840.	2.4	11
9	Feasibility and effectiveness of endoscopic irreversible electroporation for the upper gastrointestinal tract: an experimental animal study. Scientific Reports, 2021, 11, 15353.	3.3	10
10	Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. Scientific Reports, 2021, 11, 14639.	3.3	37
11	Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. PLoS ONE, 2021, 16, e0255822.	2.5	5
12	An Overview of the Genomic Characterization of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1077-1088.	3.7	8
13	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. European Journal of Gastroenterology and Hepatology, 2021, 33, 885-893.	1.6	4
14	Clinical implications of thoracic duct dilatation in patients with chronic liver disease. Medicine (United States), 2020, 99, e19889.	1.0	4
15	Silence of Hippo Pathway Associates with Pro-Tumoral Immunosuppression: Potential Therapeutic Target of Glioblastomas. Cells, 2020, 9, 1761.	4.1	7
16	Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma. Cells, 2020, 9, 2002.	4.1	25
17	How Should We Assign Large Infiltrative Hepatocellular Carcinomas for Staging?. Cancers, 2020, 12, 2589.	3.7	5
18	Differential Impact of Serum 25-Hydroxyvitamin D3 Levels on the Prognosis of Patients with Liver Cirrhosis According to MELD and Child-Pugh Scores. Journal of Korean Medical Science, 2020, 35, e129.	2.5	4

#	Article	IF	CITATIONS
19	Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine Nâ€acetylâ€Î²â€Dâ€glucosaminidase. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 234-240.	2.8	17
20	FRI-508-How reliable is initial liver resection before salvage liver transplantation and what are the predictors of dropout?. Journal of Hepatology, 2019, 70, e623.	3.7	0
21	Identification of prognostic biomarker in predicting hepatocarcinogenesis from cirrhotic liver using protein and gene signatures. Experimental and Molecular Pathology, 2019, 111, 104319.	2.1	3
22	Genomic Perspective on Mouse Liver Cancer Models. Cancers, 2019, 11, 1648.	3.7	8
23	THU-209-Dynamics of a transient elastography-based risk prediction model for hepatocellular carcinoma treated with antiviral therapy in chronic hepatitis B: A multi-center retrospective cohort study from the Korean Transient Elastography Study Group. Journal of Hepatology, 2019, 70, e255-e256.	3.7	0
24	NELFE-Dependent MYC Signature Identifies a Unique Cancer Subtype in Hepatocellular Carcinoma. Scientific Reports, 2019, 9, 3369.	3.3	9
25	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology, 2019, 156, 1368-1380.e10.	1.3	296
26	Prognostic significance of high metabolic activity in breast cancer: PET signature in breast cancer. Biochemical and Biophysical Research Communications, 2019, 511, 185-191.	2.1	14
27	Comparison of 2 curative treatment options for very early hepatocellular carcinoma. Medicine (United States), 2019, 98, e16279.	1.0	7
28	Reply. Hepatology, 2019, 69, 924-924.	7.3	0
29	Molecular Subtypes and Genomic Signatures of Hepatocellular Carcinoma for Prognostication and Therapeutic Decision-Making. Molecular and Translational Medicine, 2019, , 109-123.	0.4	3
30	The epidemiology of hepatitis B virus infection in Korea. Korean Journal of Internal Medicine, 2019, 34, 945-953.	1.7	44
31	How can we improve the performance of Model for Endâ€Stage Liver Disease sodium score in patients with hepatitis B virusâ€related decompensated liver cirrhosis commencing antiviral treatment?. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1641-1648.	2.8	7
32	Glutamine synthetase mediates sorafenib sensitivity in $\hat{l}^2$ -catenin-active hepatocellular carcinoma cells. Experimental and Molecular Medicine, 2018, 50, e421-e421.	7.7	21
33	Clinical significance of APOB inactivation in hepatocellular carcinoma. Experimental and Molecular Medicine, 2018, 50, 1-12.	7.7	37
34	Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. American Journal of Gastroenterology, 2018, 113, 1167-1176.	0.4	23
35	Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B. PLoS ONE, 2018, 13, e0199094.	2.5	7
36	Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes. Oral Oncology, 2018, 85, 44-51.	1.5	11

#	Article	IF	Citations
37	Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer. Molecular Cancer Research, 2018, 16, 1713-1723.	3.4	14
38	Abstract 3404: Clinical significance of APOB inactivation in hepatocellular carcinoma., 2018,,.		1
39	The LAW index as an accurate indicator of the initiation of antiviral treatment in patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 208-214.	2.8	2
40	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169, 1327-1341.e23.	28.9	1,794
41	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nature Communications, 2017, 8, 310.	12.8	169
42	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clinical Cancer Research, 2017, 23, 4441-4449.	7.0	342
43	Validation study associating glutaminase promoter variations with hepatic encephalopathy in East Asian populations. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 901-907.	2.8	2
44	Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 111130-111143.	1.8	34
45	Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients. Gut and Liver, 2017, 11, 417-425.	2.9	8
46	Subclinical Ascites Does Not Affect the Long-term Prognosis in Hepatitis B Virus–related Cirrhosis Patients Receiving Antivirals. Journal of Clinical Gastroenterology, 2016, 50, 676-685.	2.2	1
47	BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 467-474.	2.8	47
48	The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?. Liver International, 2016, 36, 445-453.	3.9	22
49	Diagnostic performance of gadoxetic acid (Primovist)-enhanced MR imaging versus CT during hepatic arteriography and portography for small hypervascular hepatocellular carcinoma. Medicine (United) Tj ETQq1 1 C	).7 <b>8.4</b> 314 ı	g <b>BT</b> I/Overlo
50	Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis. Clinical and Molecular Hepatology, 2016, 22, 281-285.	8.9	10
51	Treatment Response and Long-Term Outcome of Peginterferon $\hat{l}_{\pm}$ and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C. Gut and Liver, 2016, 10, 808-817.	2.9	4
52	The risk of perioperative adverse events in patients with chronic liver disease. Liver International, 2015, 35, 713-723.	3.9	11
53	Risk Factors for Developing Hyponatremia During Terlipressin Treatment. Journal of Clinical Gastroenterology, 2015, 49, 607-612.	2.2	27
54	Reply. Hepatology, 2015, 62, 653-654.	7.3	0

#	Article	IF	CITATIONS
55	Clinical Significance of Hepatitis B Virus Precore and Core Promoter Variants in Korean Patients With Chronic Hepatitis B. Journal of Clinical Gastroenterology, 2015, 49, 61-68.	2.2	7
56	Role of Hepatitis B Surface Antigen (HBsAg) in Identifying True Inactive HBsAg Carriers Infected With Genotype C Hepatitis B Virus. Journal of Clinical Gastroenterology, 2014, 48, 166-171.	2.2	9
57	Gastrectomy for the treatment of refractory gastric ulceration after radioembolization with < sup > 90 < /sup > Y microspheres. Clinical and Molecular Hepatology, 2014, 20, 300.	8.9	11
58	Psychometric Hepatic Encephalopathy Score for the detection of minimal hepatic encephalopathy in Korean patients with liver cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1695-1704.	2.8	34
59	Spinal cord injury after conducting transcatheter arterial chemoembolization for costal metastasis of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2012, 18, 316.	8.9	9
60	Fatal Hypersensitivity Reactions Induced by Re-Administration of Rifampin in an Immunocompetent Patient with Tuberculous Lymphadenopathy. Korean Journal of Medicine, 2012, 82, 115.	0.3	0
61	Comparison on the Efficacy of Disinfectants Used in Automated Endoscope Reprocessors: PHMB-DBAC versus Orthophthalaldehyde. Clinical Endoscopy, 2011, 44, 109.	1.5	10
62	Rifampin-induced Pseudomembranous Colitis with Rectosigmoid Sparing. Clinical Endoscopy, 2011, 44, 137.	1.5	4
63	Epidemiological and Clinical Characteristics of Pandemic Influenza (H1N1 2009). Infection and Chemotherapy, 2009, 42, 69.	2.3	5